Richard J. Nowak, MD, global principal MINT investigator and director of the Myasthenia Gravis Clinic at Yale University, discusses a post-hoc analysis of Uplizna (inebilixumab) on the effect of ocular manifestations in generalized myasthenia gravis (gMG).
gMG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. The condition results from a defect in the transmission of nerve impulses to muscles due to the presence of antibodies against the acetylcholine receptor in the neuromuscular junction.
Inebilizumab is a first-in-class, humanized anti-CD19 B-cell depletion therapy for gMG. It was approved for the treatment of gMG in December 2025 based on results from the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT).
At the 2026 NANOS Annual Meeting, a post-hoc analysis of the MINT clinical study was presented. This analysis focused on the ocular manifestations of gMG, which Dr. Nowak explains are present in upwards of 90% of patients.
Treatment with inebilizumab illustrated improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Qualitative Myasthenia Gravis (QMG) ocular domain scores compared to placebo at week 26 in overall AChR+ and MuSK+ populations. Additionally, In the AChR+ population at week 52, inebilizumab improved MG-ADL and QMG ocular domain scores compared to placebo.
To learn more about the MINT study and results, visit:
FDA Approves Uplizna for the Treatment of Generalized Myasthenia Gravis
Uplizna (Inebilizumab): A First in Class Approach to Generalized Myasthenia Gravis Treatment
New England Journal of Medicine
